Fifty-one patients with thyroid cancer were screened; of 36 (71%) with PD-L1–positive tumors, 22 were enrolled (per eligibility criteria) and received ≥1 dose of pembrolizumab. Here, CD274 is linked to thyroid gland carcinoma.